NCT04025372 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04025372
Title	INTREPId (INTermediate Risk Erection PreservatIon Trial)
Recruitment	Active, not recruiting
Gender	male
Phase	Phase II
Variant Requirements	No
Sponsors	Dana-Farber Cancer Institute
Indications	prostate adenocarcinoma
Therapies	Bicalutamide Darolutamide
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 11 of 11 entries

Facility	City	State	Zip	Country	Details
Associated Medical Professionals of NY	Syracuse	New York	13210	United States	Details
Beth Israel Deaconness Medical Center	Boston	Massachusetts	02115	United States	Details
Brigham and Women Hospital	Boston	Massachusetts	02115	United States	Details
Dana Farber Cancer Institute	Boston	Massachusetts	02215	United States	Details
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center	Milford	Massachusetts	01757	United States	Details
Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital	South Weymouth	Massachusetts	02190	United States	Details
NYU Langone Health	New York	New York	10016	United States	Details
NYU Long Island	Garden City	New York	11530	United States	Details
Stamford Hospital	Stamford	Connecticut	06904	United States	Details
Washington University School of Medicine in St. Louis	Saint Louis	Missouri	63108	United States	Details
XCancer Omaha / Urology Cancer Center	Omaha	Nebraska	68130	United States	Details

Showing 1 to 11 of 11 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04025372Clinical Trial Detail